We are very grateful to the supporters of the 29th International Symposium on ALS/MND, to be held in Glasgow, Scotland, UK on 7 - 9 December 2018.*
Cytokinetics is a late-stage biopharmaceutical company focussed on discovering, developing and commercialising first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders such as amyotrophic lateral sclerosis (ALS). Our product candidates are small molecules based on three distinct mechanistic platforms—glutamate modulators, myeloperoxidaseor (MPO) inhibitors, and calcitonin gene-related peptide (CGRP) receptor antagonists—which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurologic indications with high unmet need in both large markets and orphan indications.
Mitsubishi Tanabe Pharma Europe (MTPE) acts as the European Headquarters of one of Japan’s leading pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation (MTPC). Based in London, we are engaged in the management of clinical research and support for commercial requirements. Our subsidiary company, Mitsubishi Tanabe Pharma Deutschland GmbH (MTPD), based in Düsseldorf, Germany, is responsible for European commercial operations including sales, marketing of current products and launch of new products from our CNS pipeline.
Italfarmaco SpA is a private, Italian based, multinational company, operating in Italy and abroad in both the pharmaceutical and fine chemical industries. Italfarmaco developed the first formulation of riluzole as oral suspension for the treatment of amyotrophic lateral sclerosis (ALS), a severely disabling disease. This formulation, resulting from the expertise of Italfarmaco in pharmaceutical technique, is especially useful in patients with swallowing disorders in which patient treatment adherence is often impaired by the worsening of the disease. It is marketed in the UK by Ethypharm. Ethypharm is a specialty pharmaceutical company, recognised as a key partner to the NHS in the UK by offering patients high quality life-improving medicines which address medical needs with a focus in the areas of pain, addiction and critical care. The oral suspension is also marketed in Spain, Italy, France, Germany, Belgium, Greece and Israel.
Orion Pharma (UK) Ltd is a subsidiary of Orion Corporation, a pharmaceutical company based in Finland. Orion carries out extensive research with a goal of introducing new treatments into global markets. Core therapy areas in Orion’s product and research strategy are respiratory, critical care, CNS, women’s health and oncology.
*Full list of sponsors will be available in due course.